<DOC>
	<DOC>NCT01102946</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of panretinal photocoagulation plus intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic retinopathy in terms of changes in visual acuity and neovascularization area.</brief_summary>
	<brief_title>Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Retinal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age ≥ 18 years old High risk proliferative diabetic retinopathy Visual acuity ≥ 20/800 No previous laser treatment for diabetic retinopathy Previous pars plana vitrectomy Systemic thromboembolic events Uncontrolled systemic hypertension Conditions avoiding adequated documentation Previous eye surgery in the last 6 months before inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>proliferative diabetic retinopathy</keyword>
	<keyword>retinal neovascularization</keyword>
	<keyword>Angiogenesis Inhibitors</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>laser</keyword>
</DOC>